Bimagrumab: an investigational human monoclonal antibody against activin type II receptors for treating obesity
Authors:
- 10 October 2024
- journal article
- review article
- Published by Walter de Gruyter GmbH in Journal of Basic and Clinical Physiology and Pharmacology
- Vol. 35 (6) , 325-334
Abstract
Bimagrumab is a human monoclonal antibody that prevents activin type II receptors (ActRII) from functioning. This antibody has a higher affinity for muscle activin-2 receptors than natural ligands such as activin and myostatin, which act as negative muscle growth regulators. Blocking the activin receptor with bimagrumab could be a new pharmaceutical approach for managing patients with obesity and type 2 diabetes mellitus (T2DM). Bimagrumab has anabolic effects on skeletal muscle mass by preventing myostatin binding and other negative muscle growth regulators. Preclinical animal models have also shown that ActRII blockade promotes actions beyond skeletal muscle, including effects on brown adipose tissue (BAT) differentiation and activity. In a phase 2 randomized clinical trial, ActRII blockade with bimagrumab led to significant loss of total body fat mass (FM), lean mass (LM) gain, and metabolic improvements over 48 weeks in overweight or obese patients with type 2 diabetes. The trial involved [number of participants], and the results showed [specific findings]. Currently, Bimagrumab is being evaluated for its potential to treat muscle wasting, functional loss in hip fractures and sarcopenia, as well as obesity. However, it is essential to note that Bimagrumab also blocks the effects of other ActRII ligands, which play a role in the neurohormonal axes, pituitary, gonads, and adrenal glands. These observations suggest that bimagrumab might represent a new approach for treating patients with obesity and related metabolic disturbances.Keywords
This publication has 41 references indexed in Scilit:
- A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesityEuropean Journal of Clinical Pharmacology, 2024
- Antibody blockade of activin type II receptors preserves skeletal muscle mass and enhances fat loss during GLP-1 receptor agonismMolecular Metabolism, 2024
- Pharmacokinetics and Pharmacodynamics of Bimagrumab (BYM338)Clinical Pharmacokinetics, 2022
- Beyond appetite regulation: Targeting energy expenditure, fat oxidation, and lean mass preservation for sustainable weight lossObesity, 2022
- Effect of Bimagrumab vs Placebo on Body Fat Mass Among Adults With Type 2 Diabetes and ObesityJAMA Network Open, 2021
- Safety and pharmacokinetics of bimagrumab in healthy older and obese adults with body composition changes in the older cohortJournal of Cachexia, Sarcopenia and Muscle, 2020
- Effect of bimagrumab on thigh muscle volume and composition in men with casting‐induced atrophyJournal of Cachexia, Sarcopenia and Muscle, 2017
- Myostatin: more than just a regulator of muscle massDrug Discovery Today, 2012
- The role of myostatin in muscle wasting: an overviewJournal of Cachexia, Sarcopenia and Muscle, 2011
- Transgenic expression of myostatin propeptide prevents diet-induced obesity and insulin resistanceBiochemical and Biophysical Research Communications, 2005